Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Delayed Deutsche Boerse AG Other stock markets 02:03:16 2024-05-13 EDT			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.12M 1.03M 957K 1.82M 122M 1.84M 12.34M 4.8M 59.83M 4.8M 4.69M 207M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.03M 957K 1.82M 122M 1.84M 12.34M 4.8M 59.83M 4.8M 4.69M 207M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-80.45%	1.39M
LONZA GROUP AG	+1.08%	+7.56%	+3.61%	+9.84%	50.25B
REVOLUTION MEDICINES, INC.	+0.40%	-1.37%	+401.69%	+625.15%	40.39B
IQVIA HOLDINGS INC.	-0.52%	+6.57%	+25.41%	-5.37%	34.38B
BEONE MEDICINES AG	+3.97%	+6.71%	+26.06%	+63.36%	34.4B
CELLTRION, INC.	-4.19%	-1.84%	+3.76%	+32.17%	26.32B
ASCENDIS PHARMA A/S	-2.40%	+1.60%	-	-	16.64B
MEDPACE HOLDINGS, INC.	+1.34%	+5.68%	+75.77%	+141.51%	16.14B
EUROFINS SCIENTIFIC SE	-0.95%	+0.76%	+12.92%	+21.59%	13.71B
IONIS PHARMACEUTICALS, INC.	+1.69%	+3.09%	+93.44%	+99.19%	13.75B
Average	-0.02%	+2.79%	+71.41%	+100.78%	24.6B
Weighted average by Cap.	+0.29%	+4.03%	+91.39%	+141.84%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company